Effectiveness and safety of biologics in pediatric inflammatory bowel disease: Real-life data from the Sicilian Network

Romeo, Andrea; Ventimiglia, Marco; Dipasquale, Valeria; Orlando, Ambrogio; Citrano, Michele; Pellegrino, Salvatore; Accomando, Salvatore; Cottone, Mario; Romano, Claudio

doi:10.1016/j.clinre.2019.05.008

Cited by 14 publications

(16 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge, this serological combination has not previously been described in the literature and should be prospectively validated in an independent cohort. Because pANCA positivity is typical for the ulcerative colitis (UC)-like phenotype, and anti-TNF effectivity is generally lower in UC than in CD ( 9 , 12 ), it remains unclear whether the abovementioned serological combination could be a potential proxy marker of distinct disease phenotype of CD with lower sensitivity to anti-TNF treatment.…”

Section: Discussionmentioning

confidence: 99%

“…However, no direct head-to-head comparison of both anti-TNF agents has been performed in pediatric or adult patients. Several indirect comparisons, including network meta-analyses, have been published, but these rarely consider pediatric populations (3)(4)(5)(6)(7)(8)(9). Owing to the low number of pediatric patients per center, it is difficult to perform RCTs that can demonstrate differences between these drugs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation

Bronský

Copova

Kazeka

et al. 2022

Clin Transl Gastroenterol

View full text Add to dashboard Cite

INTRODUCTION:Two antitumor necrosis factor therapies (infliximab [IFX] and adalimumab [ADA]) have been approved for the treatment of pediatric Crohn's disease (CD) but have not been compared in head-to-head trials. The aim of this study was to compare the efficacy and safety of ADA and IFX by propensity score matching in a prospective cohort of pediatric patients with luminal CD and at least a 24-month follow-up.METHODS:Among 100 patients, 75 met the inclusion criteria, and 62 were matched by propensity score. We evaluated time to treatment escalation as the primary outcome and primary nonresponse, predictors of treatment escalation and relapse, serious adverse events, pharmacokinetics, and effect of concomitant immunomodulators as secondary outcomes.RESULTS:There was no difference between ADA and IFX in time to treatment escalation (HR = 0.63 [95% CI 0.31–1.28] P = 0.20), primary nonresponse (P = 0.95), or serious adverse events. The median (interquartile range) trough levels at the primary outcome were 14.05 (10.88–15.40) and 6.15 (2.08–6.58) µg/mL in the ADA and IFX groups, respectively. On a multivariate analysis, the combination of anti-Saccharomyces cerevisiae antibody negativity and antineutrophil cytoplasmic antibody positivity was a strong independent predictor of treatment escalation (HR 5.19, [95% CI 2.41–11.18], P < 0.0001). The simple endoscopic score for CD, L3 disease phenotype, and use of concomitant immunomodulators for at least the first 6 months revealed a trend toward significance on a univariate analysis.DISCUSSION:Propensity score matching did not reveal substantial differences in efficacy or safety between ADA and IFX. The anti-S. cerevisiae antibody negativity and antineutrophil cytoplasmic antibody positivity combination is a strong predictor of treatment escalation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation

Bronský

Copova

Kazeka

et al. 2022

Clin Transl Gastroenterol

View full text Add to dashboard Cite

show abstract

“…The efficacy of IFX and ADA was similar in a pediatric CD cohort study and associated with the age of diagnosis. The number of AEs was tolerable and more relative to IFX [46]. There was a difference between UC and CD.…”

Section: Discussionmentioning

confidence: 88%

“…The incidence of psoriasis was higher in female in all studies for pediatric patients, while only one study reported lower incidence in female [28]. There are significant differences in the incidence of psoriasis in the different genders in the pediatric group (7-17 years) treated with IFX [46]. And in most cohort studies of pediatric patients, TNF antagonist induced psoriasis is more predisposed to the female population [18,48].…”

Section: Discussionmentioning

confidence: 99%

A systematic review and meta-analysis: Female smokers,even former smokers lead higher incidence of psoriasis in the treatment of inflammatory bowel disease with biological agents.

Yang¹,

Liu²,

Deng

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: At present, infliximab(IFX) and adalimumab(ADA) are the classic drugs for the treatment of moderate-severe inflammatory bowel disease(IBD), which prove effective for the disease control. However, the side effects need to be monitored during the therapy process, especially the paradoxical reaction of the skin system such as psoriasis, which could greatly benefit quality of patients’ life.Aim: In order to describe and analyze TNF-antagonist-induced psoriasis in patients with inflammatory bowel disease from the aspects of incidence, pathogenesis, distribution and type of lesions, prognosis and treatment, the incidence of psoriasis induced by Infliximab (IBD) and Adalimumab (ADA) in the treatment of Inflammatory Bowel Disease Disease (IBD) as well as the relationship between sex, smoking and the incidence of psoriasis were investigated.Methods: Literatures in English language meeting the qualifications on Pubmeb, Embase, Web of Science, Google, and Geenmedical databases were searched . More than two co-authors evaluated the quality of the article and extracted the data respectively. The data obtained were statistically analyzed by statistical software of Revman and Stata.Results: 1) The incidence of psoriasis was higher in ADA Group (OR 0.66, P<0.05, 95% CI (0.52-0.84) ; 2) The incidence of psoriasis was higher in females than in males (OR 1.54, P<0.05, 95% CI (1.27-1.86)) ; 3) Smoking increased the incidence of psoriasis (OR 1.79, P<0.01, 95% CI (1.42-2.24); 4) Psoriasis is mainly distributed in the Scalp, Palmoplantar, skin folds and limbs, and often occurs in the genital organs, the pathogenesis of which is not completely clear; the interval of medication is more than one year, and the interval of medication using IFX is longer than that of ADA Group; most cases can be relieved by local hormone, phototherapy or systemic hormone therapy without changing the strategy of biological agents.Conclusion: The incidence of psoriasis induced by TNF-antagonists is higher in many autoimmune diseases. The frequency of reported in inflammatory bowel disease is higher than other autoimmune diseases, and the safety of ADA Treatment for IBD is higher than that of IFX The incidence of psoriasis is higher in women than in men; the incidence of psoriasis is significantly higher in smokers / ex-smokers than in non-smokers. The interval of drug use of TNF-antagonists may be a predictive factor for the prevention and treatment of psoriasis, and there are differences among different kinds of TNF-antagonists. Change of therapeutic strategy of TNF-antagonists is not recommended in the event of psoriasis.

show abstract

“…[ 27 ] There were significant differences in the incidence of psoriasis in the different genders of the pediatric group (7–17 years) administrated with IFX. [ 41 ] Besides, in most cohort studies on pediatric patients, TNF-d antagonist induced psoriasis was more predisposed to the female population. [ 17 , 42 ] Third, IBD patients treated with TNF-α-antagonist had a higher incidence of psoriasis in smokers than that of non-smokers.…”

Section: Discussionmentioning

confidence: 99%

The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist

Yang

Liu²,

Deng³

et al. 2021

Medicine

View full text Add to dashboard Cite

Background: Infliximab (IFX) and adalimumab (ADA) refer to the classic drugs to treat moderate-severe inflammatory bowel disease (IBD), which have been proven to be effective to control IBD. However, the side effects exerted by IFX and ADA should be monitored in therapies, especially the paradoxical reaction of the skin system (e.g., psoriasis). Psoriasis is recognized as the most common skin lesion, capable of significantly affecting the quality of patients’ life. Methods: This study searched literatures published in English language with the qualifications on PubMed, Embase, Web of Science, Google, and Geenmedical databases. Over 2 co-authors assessed the quality of the articles and extracted the data independently. The data acquired were statistically analyzed with the statistical software of Revman and Stata. Results: The ADA Group achieved a higher incidence of psoriasis (odds ratio [OR] = 0.658, 95% confidence interval [CI] [0.471–0.919]); Females achieved a higher incidence of psoriasis than males (OR = 1.941, 95%CI [1.326–2.843], P < .05); Smoking up-regulated the incidence of psoriasis (OR = 1.679, 95%CI [1.237–2.279], P < .05); The interval of medication was over 1 year, and the interval of medication applying IFX was longer than that of the ADA Group; most cases could be relieved by using local hormone, phototherapy, or systemic hormone therapy under the strategy of biological agents. Conclusions: The frequency of reported in IBD exceeds those of other autoimmune diseases, and the ADA treatment for IBD is safer than IFX. Psoriasis is more common in females than in males. Smoking refers to one of risk factors of psoriasis.

show abstract

Effectiveness and safety of biologics in pediatric inflammatory bowel disease: Real-life data from the Sicilian Network

Cited by 14 publications

References 47 publications

Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation

Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation

A systematic review and meta-analysis: Female smokers,even former smokers lead higher incidence of psoriasis in the treatment of inflammatory bowel disease with biological agents.

The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist

Contact Info

Product

Resources

About